| Recruiting | An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine NCT07132645 | University of Michigan Rogel Cancer Center | EARLY_Phase 1 |
| Recruiting | Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases NCT06788886 | Mayo Clinic | N/A |
| Recruiting | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes NCT04907643 | Cedars-Sinai Medical Center | N/A |
| Recruiting | Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant NCT04837885 | University Hospital, Bordeaux | Phase 2 |
| Completed | Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®) NCT05816720 | Novartis Pharmaceuticals | — |
| Recruiting | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor NCT05069220 | Peking Union Medical College Hospital | EARLY_Phase 1 |
| Completed | Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly NCT06570174 | Yonsei University | N/A |
| Completed | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CAB NCT04400474 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 |
| Terminated | Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel NCT04073017 | Vanderbilt-Ingram Cancer Center | N/A |
| Active Not Recruiting | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors NCT03375320 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET NCT03466216 | Orano Med LLC | Phase 1 |
| Completed | A Study of XmAb®18087 in Subjects With NET and GIST NCT03411915 | Xencor, Inc. | Phase 1 |
| Completed | Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor NCT03197012 | Thomas Hope | EARLY_Phase 1 |
| Active Not Recruiting | Surgical Intervention and the NETest NCT03012789 | Wren Laboratories LLC | N/A |
| Completed | DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor NCT03143946 | University Medical Center Groningen | N/A |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) NCT02628067 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor NCT02472678 | University Medical Center Groningen | N/A |
| Completed | Optimal Feeding for NET Patients NCT02481804 | University Medical Center Groningen | N/A |
| Enrolling By Invitation | RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide NCT02270567 | Wren Laboratories LLC | — |
| Terminated | GA-68 DOTA-TOC of Somatostatin Positive Malignancies NCT02177773 | University of California, San Francisco | Phase 1 / Phase 2 |
| Completed | Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study NCT02147106 | University Medical Center Groningen | — |
| Unknown | 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors NCT02038738 | Ochsner Health System | Phase 1 / Phase 2 |
| Unknown | Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors NCT02092714 | Fox Chase Cancer Center | — |
| Completed | Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study NCT01849523 | University Medical Center Groningen | N/A |
| Completed | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT NCT01869725 | Sue O'Dorisio | Phase 2 |
| Completed | A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal T NCT01476592 | University of Wisconsin, Madison | N/A |
| Unknown | Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to th NCT01448083 | Nuclear Medicine Consultants, Inc. | — |
| Completed | Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor NCT01099540 | Samsung Medical Center | Phase 2 |
| Completed | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors NCT01024387 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors NCT00942682 | Dana-Farber Cancer Institute | Phase 1 |
| Withdrawn | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) NCT01048086 | University of Iowa | Phase 2 |
| Unknown | Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors NCT00569738 | Hadassah Medical Organization | — |
| Completed | Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors NCT00804336 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Gastrointestinal Motility in Patients With Neuroendocrine Tumors NCT00789841 | University of Aarhus | — |
| Active Not Recruiting | Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or L NCT00569127 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization NCT00434109 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemo NCT00363051 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors NCT00227617 | University of California, San Francisco | Phase 2 / Phase 3 |
| Completed | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors NCT00131911 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors NCT00165230 | Dana-Farber Cancer Institute | Phase 2 |